IRIS

Sfoglia per Autore  

Opzioni
Mostrati risultati da 1 a 20 di 83
Titolo Data di pubblicazione Autore(i) File
Possible antioxidant role of SPA therapy with chlorine-sulphur-bicarbonate mineral water. 1-gen-2009 Costantino, M; Giuberti, G; Caraglia, Michele; Lombardi, A; Misso, Gabriella; Abbruzzese, A; Ciani, F; Lampa, E.
Emerging strategies to strengthen the anti-tumour activity of type I IFNs: overcoming survival pathways 1-gen-2009 Caraglia, Michele; Marra, M.; Lamberts, S. W. J.; Zappavigna, S.; Misso, Gabriella; Cavagnini, F.; Abbruzzese, A.; Hofland, L. J.; Vitale, G.
W7FW14F apomyoglobin amyloid aggregates-mediated apoptosis is due to oxidative stress and AKT inactivation caused by Ras and Rac 1-gen-2009 Sirangelo, Ivana; Iannuzzi, Clara; Vilasi, S; Irace, Gaetano; Giuberti, G; Misso, Gabriella; D'Alessandro, A; ABBRUZZESE SACCARDI, A; Caraglia, Michele
Cytotoxic drugs up-regulate Epidermal Growth Factor Receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted Antibody-Dependent-Cell-mediated-Cytotoxicity (ADCC) 1-gen-2010 Correale, P; Remando, C; Migali, C; Marra, M; Misso, Gabriella; Arcuri, Fp; DEL VECCHIO, Mt; Carducci, A; Loiacono, L; Tagliaferri, P; Abbruzzese, A; Arancini, G; Caraglia, Michele
Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin 1-gen-2010 Gazzerro, P; Malfitano, Am; Proto, Mc; Santoro, A; Pisanti, S; Caruso, Mg; Notarnicola, M; Messa, C; Laezza, C; Misso, Gabriella; Caraglia, Michele; Bifulco, M.
"Phase II trial of bevacizumab and dose/dense chemoterapy with cisplatin and metronomic daily oral etoposide in advanced non small cell lung cancer patients" 1-gen-2011 Correale, P; Botta, C; Basile, A; Pagliuchi, M; Licchetta, A; Martellucci, I; Bestoso, E; Apollinari, S; Addeo, R; Misso, Gabriella; Romano, O; Abbruzzese, A; Lamberti, Monica; Luzzi, L; Gotti, G; Rotundo, M; Caraglia, Michele; Tagliaferri, P.
Immune-modulating Effects of the Newest Cetuximab-based Chemoimmunotherapy Regimen in Advanced Colorectal Cancer Patients. 1-gen-2012 Botta, C; Bestoso, E; Apollinari, S; Cusi, Mg; Pastina, P; Abbruzzese, A; Sperlongano, Pasquale; Misso, Gabriella; Caraglia, Michele; Tassone, P; Tagliaferri, P; Correale, P.
Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. 1-gen-2012 Misso, Gabriella; Porru, M; Stoppacciaro, A; Castellano, M; De Cicco, F; Leonetti, C; Santini, D; Caraglia, Michele
Core-shell biodegradable nanoassemblies for the passive targeting of docetaxel: features, antiproliferative activity and in vivo toxicity. 1-gen-2012 Ungaro, F; Conte, C; Ostacolo, L; Maglio, G; Barbieri, A; Arra, C; Misso, Gabriella; Abbruzzese, A; Caraglia, Michele; Quaglia, F.
Tumour-specific uptake of anti-cancer drugs: the future is here. 1-gen-2012 Caraglia, Michele; Marra, M; Misso, Gabriella; Lamberti, Monica; Salzano, G; De Rosa, G; Abbruzzese, A.
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. 1-gen-2012 Amodio, N; Di Martino, Mt; Foresta, U; Leone, E; Lionetti, M; Leotta, M; Gullà, Am; Pitari, Mr; Conforti, F; Rossi, M; Agosti, V; Fulciniti, M; Misso, Gabriella; Morabito, F; Ferrarini, M; Neri, A; Caraglia, Michele; Munshi, Nc; Anderson, Kc; Tagliaferri, P; Tassone, P.
MOLECULAR TARGETS FOR THE TREATMENT OF MULTIPLE MYELOMA 1-gen-2012 Rossi, M; Di Martino, Mt; Morelli, E; Leotta, M; Rizzo, Antonietta; Grimaldi, A; Misso, Gabriella; Tassone, P; Caraglia, Michele
Bisphosphonates and cancer: what opportunities from nanotechnology? 1-gen-2013 De Rosa, G; Misso, Gabriella; Salzano, G; Caraglia, Michele
Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC. 1-gen-2013 Misso, Gabriella; Giuberti, G; Lombardi, A; Grimaldi, A; Ricciardiello, F; Giordano, A; Tagliaferri, P; Abbruzzese, A; Caraglia, Michele
Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies. 1-gen-2013 Vitale, G; Lupoli, G; Guarrasi, R; Colao, A; Dicitore, A; Gaudenzi, G; Misso, Gabriella; Castellano, M; Addeo, R; Facchini, G; Del Prete, S; Caraglia, Michele
Aminobisphosphonates and nano technologically-modified aminobisphosphonates: A new dawn in the treatment of bone and extra-bone tumors? 1-gen-2013 Caraglia, M.; Misso, G.; Santini, D.
Emerging pathways as individualized therapeutic target of multiple myeloma. 1-gen-2013 Misso, Gabriella; Zappavigna, S; Castellano, M; De Rosa, G; Di Martino, Mt; Tagliaferri, P; Tassone, P; Caraglia, Michele
Transferrin-Conjugated SNALPs Encapsulating 2'-O-Methylated miR-34a for the Treatment of Multiple Myeloma 1-gen-2014 Scognamiglio, I; Di Martino, Mt; Campani, V; Virgilio, A; Galeone, A; Gullà, A; Gallo Cantafio, Me; Misso, Gabriella; Tagliaferri, P; Tassone, P; Caraglia, Michele; De Rosa, G.
Myrtucommulone production by a strain of Neofusicoccum australe endophytic in myrtle (Myrtus communis). 1-gen-2014 Nicoletti, R; Ferranti, P; Caira, S; Misso, Gabriella; Castellano, M; Di Lorenzo, G; Caraglia, Michele
Mir-34: a new weapon against cancer? 1-gen-2014 Misso, Gabriella; Di Martino, Mt; De Rosa, G; Farooqi, Aa; Lombardi, A; Campani, V; Zarone, Mr; Gullà, A; Tagliaferri, P; Tassone, P; Caraglia, Michele
Mostrati risultati da 1 a 20 di 83
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile